Home › Glioblastoma › NCT07831369

VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma

Who can join

Ages 18 to 98 · All sexes

Inclusion Criteria:

* Diagnosis of glioblastoma or IDH-mutated glioma by WHO 2021 classification
* For glioblastoma, at least one prior treatment, which needs to include temozolomide and/or radiation
* For IDH-mutated glioma, prior treatment with both radiation and alkylating chemotherapy
* Evidence of progression by RANO 2.0 criteria on MRI within last four weeks
* At least 1 enhancing measurable lesion

Exclusion Criteria:

* Use of an enzyme-inducing antiepileptic or other strong inducer of CYP3A4
* Prior treatment with irinotecan
* Prior use of valproic acid within 2 months
* Anticancer treatment within 4 weeks, 6 weeks if nitrosourea
* Active bacterial or fungal infection requiring systemic treatment
* Pregnancy
* Known mitochondrial disease

About the study

The goal of this clinical trial is to see if the combination of valproic acid, irinotecan, and simvastatin causes these tumors to stabilize or shrink, which is a sign that these combinations are effective against tumors in patients with recurrent glioblastoma and adults with recurrent IDH-mutated gliomas

What is being tested

• Valproic Acid (VPA) (drug)
• Irinotecan (drug)
• Simvastatin (drug)

Sponsor: Inova Health Care Services · Participants: 52 · Started: Sep 4, 2026

Contact the study team

• Keary Jane't · Phone: (571) 472-3173
• Takada Harris · Phone: (571) 472-0618

Official record on ClinicalTrials.gov — NCT07831369

Locations in the U.S.

Conditions

• Glioblastoma
• Astrocytoma

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.